FPF
SRPT icon

FNY Partners Fund’s Sarepta Therapeutics SRPT Stock Holding History

FNY Partners Fund’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-50
Closed -$2K – 595
2017
Q3 		$2K Sell
50
-50
-50% -$2K ﹤0.01% 501
2017
Q2 		$3K Buy
100
+60
+150% +$1.95K ﹤0.01% 462
2017
Q1 		$1K Sell
40
-49
-55% -$1.52K ﹤0.01% 1351
2016
Q4 		$2K Buy
+89
New +$3.58K ﹤0.01% 516

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

FNY Partners Fund's SRPT Position: Q1 2018 in Review

FNY Partners Fund reduced its Sarepta Therapeutics (SRPT) stake by 61% in Q1 2018, selling an estimated $613K and leaving 5,800 shares worth $429K. The position accounts for 0.23% of the portfolio, ranked #65.

FNY Partners Fund first reported a position in SRPT in Q4 2016 and has held it in 6 quarters since. The position peaked at $2.37M in Q2 2017. 269 funds tracked by Wall St. Rank hold SRPT as of Q1 2018.

  • FNY Partners Fund held 5,800 shares of Sarepta Therapeutics worth $429K as of Q1 2018.
  • FNY Partners Fund sold 9,200 Sarepta Therapeutics shares in Q1 2018, an estimated $613K.
  • Sarepta Therapeutics made up 0.23% of FNY Partners Fund's portfolio in Q1 2018, its #65 holding.
  • FNY Partners Fund first reported a position in Sarepta Therapeutics in Q4 2016 and has held it in 6 quarters since.
  • FNY Partners Fund's Sarepta Therapeutics position peaked at $2.37M in Q2 2017.
  • 269 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2018.

Based on FNY Partners Fund's 13F filing for Q1 2018, filed 18 Apr 2018.